#BEGIN_DRUGCARD DB08880

# AHFS_Codes:
Not Available

# ATC_Codes:
Not Available

# Absorption:
After oral administration of teriflunomide, maximum plasma concentrations are reached, on average, in 1-4 hours.

# Biotransformation:
Teriflunomide mainly undergoes hydrolyis to minor metabolites. Other minor metabolic pathways include oxidation, N-acetylation and sulfate conjugation. Teriflunomide is not metabolized by CYP450 or flavin monoamine oxidase.

# Brand_Mixtures:
Not Available

# Brand_Names:
Aubagio®

# CAS_Registry_Number:
163451-81-8

# ChEBI_ID:
68540

# Chemical_Formula:
Not Available

# Chemical_IUPAC_Name:
Not Available

# Chemical_Structure:
Not Available

# Creation_Date:
2013-05-19 20:55:27 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. The FDA label states an important warning about the risk of hepatoxicity and teratogenicity for patients using teriflunomide.

# Dosage_Forms:
Tablet	Oral
Tablet	Oral

# Drug_Category:
Pyrimidine Synthesis Inhibitor

# Drug_Interactions:
Leflunomide	Avoid combination due to increased adverse effects of teriflunomide.
Natalizumab	Avoid combination due to the increased risk of infection.
Pimecrolimus	Avoid combination due to the increased toxic effects of immunosuppressants.
Tacrolimus	Avoid combination due to the increased toxic effects of immunosuppressants.

# Drug_Reference:
16567708	O'Connor PW, Li D, Freedman MS, Bar-Or A, Rice GP, Confavreux C, Paty DW, Stewart JA, Scheyer R: A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology. 2006 Mar 28;66(6):894-900.
18782502	Tallantyre E, Evangelou N, Constantinescu CS: Spotlight on teriflunomide. Int MS J. 2008 Jun;15(2):62-8.

# Drug_Type:
Approved
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Soluble in DMSO (practically insoluble in water).

# Food_Interactions:
Food does not affect teriflunomide pharmacokinetics, so take with or without food.

# GenBank_ID:
Not Available

# Generic_Name:
Teriflunomide

# HET_ID:
Not Available

# Half_Life:
The median half-life is 18 to 19 days.

# InChI_Identifier:
Not Available

# InChI_Key:
Not Available

# Indication:
Used in the treatment of relapsing forms of multiple sclerosis (MS).

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
D10172

# LIMS_Drug_ID:
8893

# Mechanism_Of_Action:
The exact mechanism by which teriflunomide acts in MS is not known. What is known is that teriflunomide prevents pyrimidine synthesis by inhibiting the mitochondrial enzyme
dihydroorotate dehydrogenase, and this may be involved in its immunomodulatory effect in MS.

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
Not Available

# Molecular_Weight_Mono:
Not Available

# Organisms_Affected:
Humans and other mammals

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
Not Available

# Pharmacology:
Teriflunomide is an immunomodulatory agent that decreases the amount of activated CNS lymphocytes, which results in anti-inflammatory and antiproliferative effects.

# Predicted_LogP_Hydrophobicity:
0

# Predicted_LogS:
0

# Predicted_Water_Solubility:
Not Available

# Primary_Accession_No:
DB08880

# Protein_Binding:
Teriflunomide is extensively plasma protein bound(>99%).

# PubChem_Compound_ID:
Not Available

# PubChem_Substance_ID:
Not Available

# RxList_Link:
http://www.rxlist.com/aubagio-drug.htm

# Salts:
Not Available

# Secondary_Accession_No:
Not Available

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
Not Available

# State:
solid

# Structure:
0

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
A-771726
HMR1726

# Synthesis_Reference:
Not Available

# Toxicity:
Teriflunomide is contraindicated in pregnant women or women of childbearing age due to the risk of teratogenicity. Teriflunomide is also contraindicated in severe hepatic impairment due to reports of hepatotoxicity, hepatic failure, and death.

# Update_Date:
2013-05-20 17:10:23 -0600

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Teriflunomide

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Mitochondrion
mitochondrial inner membrane

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
21157651	Palmer AM: Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis. Curr Opin Investig Drugs. 2010 Nov;11(11):1313-23.
8573583	Davis JP, Cain GA, Pitts WJ, Magolda RL, Copeland RA: The immunosuppressive metabolite of leflunomide is a potent inhibitor of human dihydroorotate dehydrogenase. Biochemistry. 1996 Jan 30;35(4):1270-3.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
DHODH

# Drug_Target_1_GenBank_ID_Gene:
M94065

# Drug_Target_1_GenBank_ID_Protein:
555594

# Drug_Target_1_GeneCard_ID:
DHODH

# Drug_Target_1_Gene_Name:
DHODH

# Drug_Target_1_Gene_Sequence:
>1191 bp
AAATTACCGTGGAGACACCTGCAAAAGCGGGCCCAGGATGCTGTGATCATCCTGGGGGGA
GGAGGACTTCTCTTCGCCTCCTACCTGATGGCCACGGGAGATGAGCGTTTCTATGCTGAA
CACCTGATGCCGACTCTGCAGGGGCTGCTGGACCCGGAGTCAGCCCACAGACTGGCTGTT
CGCTTCACCTCCCTGGGGCTCCTTCCACGGGCCAGATTTCAAGACTCTGACATGCTGGAA
GTGAGAGTTCTGGGCCATAAATTCCGAAATCCAGTAGGAATTGCTGCAGGATTTGACAAG
CATGGGGAAGCCGTGGACGGACTTTATAAGATGGGCTTTGGTTTTGTTGAGATAGGAAGT
GTGACTCCAAAACCTCAGGAAGGAAACCCTAGACCCAGAGTCTTCCGCCTCCCTGAGGAC
CAAGCTGTCATTAACAGGTATGGATTTAACAGTCACGGGCTTTCAGTGGTGGAACACAGG
TTACGGGCCAGACAGCAGAAGCAGGCCAAGCTCACAGAAGATGGACTGCCTCTGGGGGTC
AACTTGGGGAAGAACAAGACCTCAGTGGACGCCGCGGAGGACTACGCAGAAGGGGTGCGC
GTACTGGGCCCCCTGGCCGACTACCTGGTGGTGAATGTGTCCAGCCCCAACACTGCCGGG
CTGCGGAGCCTTCAGGGAAAGGCCGAGCTGCGCCGCCTGCTGACCAAGGTGCTGCAGGAG
AGGGATGGCTTGCGGAGAGTGCACAGGCCGGCAGTCCTGGTGAAGATCGCTCCTGACCTC
ACCAGCCAGGATAAGGAGGACATTGCCAGTGTGGTCAAAGAGTTGGGCATCGATGGGCTG
ATTGTTACGAACACCACCGTGAGTCGCCCTGCGGGCCTCCAGGGTGCCCTGCGCTCTGAA
ACAGGAGGGCTGAGTGGGAAGCCCCTCCGGGATTTATCAACTCAAACCATTCGGGAGATG
TATGCACTCACCCAAGGCCGAGTTCCCATAATTGGGGTTGGTGGTGTGAGCAGCGGGCAG
GACGCGCTGGAGAAGATCCGGGCAGGGGCCTCCCTGGTGCAGCTGTACACGGCCCTCACC
TTCTGGGGGCCACCCGTTGTGGGCAAAGTCAAGCGGGAACTGGAGGCCCTTCTGAAAGAG
CAGGGCTTTGGCGGAGTCACAGATGCCATTGGAGCAGATCATCGGAGGTGA

# Drug_Target_1_General_Function:
Nucleotide transport and metabolism

# Drug_Target_1_General_References:
1446837	Minet M, Dufour ME, Lacroute F: Cloning and sequencing of a human cDNA coding for dihydroorotate dehydrogenase by complementation of the corresponding yeast mutant. Gene. 1992 Nov 16;121(2):393-6.

# Drug_Target_1_HGNC_ID:
HGNC:2867

# Drug_Target_1_HPRD_ID:
00521

# Drug_Target_1_ID:
424

# Drug_Target_1_Locus:
16q22

# Drug_Target_1_Molecular_Weight:
42868

# Drug_Target_1_Name:
Dihydroorotate dehydrogenase, mitochondrial

# Drug_Target_1_Number_of_Residues:
395

# Drug_Target_1_PDB_ID:
1D3H

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF01180	DHO_dh

# Drug_Target_1_Protein_Sequence:
>Dihydroorotate dehydrogenase, mitochondrial precursor
MAWRHLKKRAQDAVIILGGGGLLFASYLMATGDERFYAEHLMPTLQGLLDPESAHRLAVR
FTSLGLLPRARFQDSDMLEVRVLGHKFRNPVGIAAGFDKHGEAVDGLYKMGFGFVEIGSV
TPKPQEGNPRPRVFRLPEDQAVINRYGFNSHGLSVVEHRLRARQQKQAKLTEDGLPLGVN
LGKNKTSVDAAEDYAEGVRVLGPLADYLVVNVSSPNTAGLRSLQGKAELRRLLTKVLQER
DGLRRVHRPAVLVKIAPDLTSQDKEDIASVVKELGIDGLIVTNTTVSRPAGLQGALRSET
GGLSGKPLRDLSTQTIREMYALTQGRVPIIGVGGVSSGQDALEKIRAGASLVQLYTALTF
WGPPVVGKVKRELEALLKEQGFGGVTDAIGADHRR

# Drug_Target_1_Reaction:
(S)-dihydroorotate + O2 = orotate + H2O2

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Not Available

# Drug_Target_1_SwissProt_ID:
Q02127

# Drug_Target_1_SwissProt_Name:
PYRD_HUMAN

# Drug_Target_1_Synonyms:
DHOdehase
Dihydroorotate dehydrogenase, mitochondrial precursor
Dihydroorotate oxidase
EC 1.3.3.1

# Drug_Target_1_Theoretical_pI:
10.23

# Drug_Target_1_Transmembrane_Regions:
13-32

#END_DRUGCARD DB08880
